Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.

Abstract

The combination of Ftorafur (NSC-148958) and methyl-CCNU (NSC-95441) was evaluated in 36 patients with advanced colorectal cancer. The principle toxicities encountered were myelosuppression, gastrointestinal, and neurological. There were no complete responses and only 5/34 (14.7%) patients achieved a partial response. Methyl-CCNU and Ftorafur does not appear to be an effective combination in advanced adenocarcinoma of the colon and rectum.

• Authors: R J Belt, R Stephens
• Journal: Cancer (Cancer) Vol. 44 Issue 3 Pg. 869-72 (Sep 1979) ISSN: 0008-543X [Print] United States
• PMID: 383275 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Nitrosourea Compounds
• Semustine
• Tegafur
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Bone Marrow (drug effects)
• Colonic Neoplasms (drug therapy)
• Digestive System (drug effects)
• Drug Evaluation
• Drug Therapy, Combination
• Fluorouracil (analogs & derivatives)
• Humans
• Middle Aged
• Nervous System (drug effects)
• Nitrosourea Compounds (administration & dosage)
• Rectal Neoplasms (drug therapy)
• Semustine (administration & dosage, adverse effects, toxicity)
• Tegafur (administration & dosage, adverse effects)